Skip to main content

The rockefeller university

Calendar of Events & Lectures

Displaying 4 of 3169 events.
Today
This Week

Tuesday, December 17, 2024

Dissecting the Pathological Complexities of Neurodegeneration with In Vitro Models of the Human Brain

| CASPARY AUDITORIUM
Seminars, Tri-Institutional Seminars at Rockefeller
Joel W. Blanchard, Ph.D., assistant professor, departments of neuroscience, cell, developmental, and regenerative biology, Icahn School of Medicine at Mount Sinai

Mhc-I Peptide Selection by the Transporter Associated with Antigen Processing

| 101 ROCKEFELLER RESEARCH LABORATORIES, MSKCC, 430 E. 67TH ST.
Tri-Institutional Events (at MSK & WCM), Other Tri-Institutional Events
Structural Biology Research Seminar
James Lee, Ph.D., postdoctoral researcher, Laboratory of Membrane Biology and Biophysics, The Rockefeller University

Targeting Chromatin Regulatory Proteins with Therapeutic Degraders

| AUDITORIUM, ROCKEFELLER RESEARCH LABORATORIES, MSKCC, 430 E. 67TH ST.
Tri-Institutional Events (at MSK & WCM), Molecular Pharmacology and Chemistry Program
Danette Daniels, Ph.D., vice president, protein degradation platform, Foghorn Therapeutics

Neural Mechanisms of Strategy-dependent Decision-making in the Prefrontal Cortex

| A LEVEL PHYSICS SEMINAR ROOM, ROOM A30, SMITH HALL ANNEX (CRC)
Seminars, Center for Studies in Physics and Biology Seminars
Giancarlo La Camera, Ph.D., associate professor, Stony Brook University

Tri-Institutional Calendars

The close proximity among the three institutions which comprise the Tri-I has led to a culture that encourages interinstitutional interactions and shared resources, including access to lectures and seminars from internationally renowned scientists and clinicians:

Upcoming Events

What Is the Role of Reactive Astrocytes in Neurodegenerative Disease?

| CARSON FAMILY AUDITORIUM (CRC)

Pre-Seminar Coffee and Cookies

| LOWER LEVEL GREENBERG BUILDING (CRC)

Neurobiology of Economic Choice

| CARSON FAMILY AUDITORIUM (CRC)

News

Unique characteristics of a rare liver cancer identified as clinical trial of new treatment begins  

Long classified as a subset of common liver cancer, FLC should be considered its own unique disease. Now researchers are testing a combination drug therapy that targets FLC tumors.

New mechanism for maintaining genome stability discovered

New research reveals how the RapA enzyme protects against R-loop cytotoxicity in E. coli.

Svetlana Mojsov receives Frontiers of Knowledge Award

She shares the award with three other scientists who together laid the groundwork for a new generation of drugs used to treat type 2 diabetes and obesity.

Room Reservation Calendar